Keros Therapeutics Inc (NASDAQ: KROS) kicked off on Monday, down -4.09% from the previous trading day, before settling in for the closing price of $70.00. Over the past 52 weeks, KROS has traded in a range of $27.31-$73.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -40.00%. While this was happening, its average annual earnings per share was recorded -0.06%. With a float of $30.20 million, this company’s outstanding shares have now reached $39.26 million.
The extent of productivity of a business whose workforce counts for 136 workers is very important to gauge. In terms of profitability, gross margin is -27.5%, operating margin of -31341.63%, and the pretax margin is -27890.94%.
Keros Therapeutics Inc (KROS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Keros Therapeutics Inc is 25.43%, while institutional ownership is 79.02%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -0.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.80% during the next five years compared to -111.11% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Take a look at Keros Therapeutics Inc’s (KROS) current performance indicators. Last quarter, stock had a quick ratio of 19.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4533.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.21, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -5.36 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
The latest stats from [Keros Therapeutics Inc, KROS] show that its last 5-days average volume of 0.56 million was superior to 0.38 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 82.09%. Additionally, its Average True Range was 3.58.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 82.29%, which indicates a significant increase from 73.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.49% in the past 14 days, which was higher than the 49.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $60.49, while its 200-day Moving Average is $55.61. Now, the first resistance to watch is $70.73. This is followed by the second major resistance level at $74.33. The third major resistance level sits at $76.28. If the price goes on to break the first support level at $65.18, it is likely to go to the next support level at $63.23. The third support level lies at $59.63 if the price breaches the second support level.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
The company with the Market Capitalisation of 2.95 billion has total of 40,507K Shares Outstanding. Its annual sales at the moment are 150 K in contrast with the sum of -152,990 K annual income. Company’s last quarter sales were recorded 390 K and last quarter income was -52,960 K.
